Adjunctive CBD for Schizophrenia: Small Positive-Symptom Benefits and a Negative-Symptom Null Result
A 2026 meta-analysis found a small advantage for adjunctive CBD on some schizophrenia symptom measures, but no statistically significant benefit on the negative-symptom subscale. Its results support a narrower conclusion than saying CBD improved every aspect of schizophrenia.
The analysis concerned CBD added to treatment
Di Francesco and colleagues included five randomized controlled trials in their synthesis. The clinical question was principally CBD augmentation compared with placebo, addressing symptoms remaining during treatment. Findings from that setting should not be converted into evidence that CBD can replace established antipsychotic medication. They also do not establish comparable effects from a retail cannabis product containing THC.
Different symptom scales produced different results
The pooled mean difference on the PANSS total score was −1.91, with a 95% confidence interval of −3.726 to −0.102. Positive and general symptom subscales also favored CBD statistically. The negative-symptom subscale did not show a significant effect. A total-score improvement can therefore coexist with a null result for a particular symptom cluster; it does not erase that distinction.
Statistical significance is not the same as a large clinical benefit
The authors characterized the advantages as small and called for larger trials to clarify clinical impact. Dropout rates were not significantly different between CBD and placebo. That retention result does not independently establish freedom from adverse effects or long-term safety. Although reported heterogeneity was low, five trials remain a limited basis for broad conclusions about all patients and treatment circumstances.
Interpreting the evidence
These are human trial findings summarized by a systematic review, rather than evidence from an animal psychosis model. The supported claim concerns small average changes on specified scales under studied conditions. It does not justify medication changes or a claim that cannabis generally treats schizophrenia.
Related reading: evidence for specific cannabinoid medicines.
Research reference
Antonio Di Francesco; Pierfelice Cutrufelli; Cecilia Chiarenza; et al. (2026). Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience. doi:10.1007/s00406-026-02249-3. Evidence basis: review/commentary abstract and selected explanatory passages.
